Elisa Marabotto

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9339704/publications.pdf

Version: 2024-02-01

97 papers	2,687 citations	249298 26 h-index	214428 50 g-index
97 all docs	97 docs citations	97 times ranked	2719 citing authors

#	Article	IF	Citations
1	Systematic Review: esophageal motility patterns in patients with eosinophilic esophagitis. Digestive and Liver Disease, 2022, 54, 1143-1152.	0.4	20
2	Pharmacotherapies in eosinophilic esophagitis: state of the art. Minerva Gastroenterology, 2022, 68, 69-76.	0.3	0
3	Diabetes medications and risk of HCC. Hepatology, 2022, 76, 1880-1897.	3.6	39
4	Towards a more precise classification of esophageal motility disorders in patients with systemic sclerosis. Neurogastroenterology and Motility, 2022, 34, e14416.	1.6	1
5	Recent insights on functional heartburn and reflux hypersensitivity. Current Opinion in Gastroenterology, 2022, 38, 417-422.	1.0	5
6	Advancements in the use of 24-hour impedance-pH monitoring for GERD diagnosis. Current Opinion in Pharmacology, 2022, 65, 102264.	1.7	4
7	Achalasia and Obstructive Motor Disorders Are Not Uncommon in Patients With Eosinophilic Esophagitis. Clinical Gastroenterology and Hepatology, 2021, 19, 1554-1563.	2.4	34
8	Applicability of Parameters for the Noninvasive Diagnosis of Esophageal Varices Needing Treatment to Hepatitis C Virusâ€“Cured Patients. Clinical Infectious Diseases, 2021, 72, 1862-1863.	2.9	1
9	COVIDâ€19 and liver disease: Not all evil comes to harm. Liver International, 2021, 41, 237-238.	1.9	11
10	Proactive Measures Aimed at Improving Appropriateness of Use of Proton Pump Inhibitors in Clinical Practice. Clinical Gastroenterology and Hepatology, 2021, 19, 410.	2.4	0
11	Pharmacological Management of Gastro-Esophageal Reflux Disease: An Update of the State-of-the-Art. Drug Design, Development and Therapy, 2021, Volume 15, 1609-1621.	2.0	21
12	Prevention Strategies for Esophageal Cancerâ€”An Expert Review. Cancers, 2021, 13, 2183.	1.7	19
13	Sleeve gastrectomy may double the risk of esophageal adenocarcinoma in morbidly obese patients. Surgery for Obesity and Related Diseases, 2021, 17, 1029-1030.	1.0	3
14	Refractoriness to Treatment Suggests That Clinical Evaluation Should Go Beyond the Diagnosis of Reflux Disease. Clinical Gastroenterology and Hepatology, 2021, 19, 1077-1078.	2.4	0
15	Dietary Management of Eosinophilic Esophagitis: Tailoring the Approach. Nutrients, 2021, 13, 1630.	1.7	21
16	Novel impedanceâ€pH parameters are associated with proton pump inhibitor response in patients with inconclusive diagnosis of gastroâ€oesophageal reflux disease according to Lyon Consensus. Alimentary Pharmacology and Therapeutics, 2021, 54, 412-418.	1.9	42
17	Editorial: inconclusive diagnosis of GERD: are new parameters in impedanceâ€pHmetry ready for clinical use? Authors' reply. Alimentary Pharmacology and Therapeutics, 2021, 54, 498-499.	1.9	2
18	An update of pharmacology, efficacy, and safety of vonoprazan in acid-related disorders. Expert Review of Gastroenterology and Hepatology, 2021, , 1-10.	1.4	4

#	Article	IF	Citations
19	Eradication of hepatitis C virus infection disclosing a previously hidden, underlying autoimmune hepatitis: Autoimmune hepatitis and HCV. Annals of Hepatology, 2020, 19, 222-225.	0.6	5
20	Esophageal reflux hypersensitivity: Non-GERD or still GERD?. Digestive and Liver Disease, 2020, 52, 1413-1420.	0.4	16
21	Nuts and Non-Alcoholic Fatty Liver Disease: Are Nuts Safe for Patients with Fatty Liver Disease?. Nutrients, 2020, 12, 3363.	1.7	16
22	Surveillance for Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease: Universal or Selective?. Cancers, 2020, 12, 1422.	1.7	41
23	Latest insights into the hot question of proton pump inhibitor safety â€“ a narrative review. Digestive and Liver Disease, 2020, 52, 842-852.	0.4	25
24	Appropriateness of proton pump inhibitors treatment in clinical practice: Prospective evaluation in outpatients and perspective assessment of drug optimisation. Digestive and Liver Disease, 2020, 52, 862-868.	0.4	11
25	A SIGE-SINGEM-AIGO technical review on the clinical use of esophageal reflux monitoring. Digestive and Liver Disease, 2020, 52, 966-980.	0.4	27
26	Risk factors for bleeding following oesophageal band ligation: Providing further evidence to ameliorate clinical practice. Digestive and Liver Disease, 2020, 52, 792-793.	0.4	0
27	The Lyon Consensus: Does It Differ From the Previous Ones?. Journal of Neurogastroenterology and Motility, 2020, 26, 311-321.	0.8	26
28	Bile reflux in patients with nerd is associated with more severe heartburn and lower values of mean nocturnal baseline impedance and chemical clearance. Neurogastroenterology and Motility, 2020, 32, e13919.	1.6	23
29	Vonoprazan Fumarate for the Treatment of Gastric Ulcers: A Short Review on Emerging Data . Clinical and Experimental Gastroenterology, 2020, Volume 13, 99-104.	1.0	14
30	Pathophysiology, diagnosis, and pharmacological treatment of gastro-esophageal reflux disease. Expert Review of Clinical Pharmacology, 2020, 13, 437-449.	1.3	21
31	Course of oesophageal varices and performance of noninvasive predictors following Hepatitis C Virus clearance in compensated advanced chronic liver disease. European Journal of Clinical Investigation, 2020, 50, e13231.	1.7	8
32	Comparison of Two Different Techniques to Assess Adalimumab Trough Levels in Patients with Crohnâ€™s Disease. Journal of Gastrointestinal and Liver Diseases, 2020, 24, 451-456.	0.5	21
33	Eosinophilic esophagitis and biologics. Minerva Gastroenterology, 2020, , .	0.3	1
34	A Closer Look at Factors Associated With Bleeding in Cirrhotic Patients. American Journal of Gastroenterology, 2019, 114, 364-365.	0.2	1
35	The prevention of NSAID-induced gastric ulcers is a firmly established PPI indication. Expert Review of Clinical Pharmacology, 2019, 12, 1011-1012.	1.3	1
36	Updates in the field of non-esophageal gastroesophageal reflux disorder. Expert Review of Gastroenterology and Hepatology, 2019, 13, 827-838.	1.4	31

#	Article	IF	Citations
37	Advancements in the use of manometry and impedance testing for esophageal functional disorders. Expert Review of Gastroenterology and Hepatology, 2019, 13, 425-435.	1.4	10
38	Hepatocellular Carcinoma Intermediate Stage Subclassification Systems: One, None, and One Hundred Thousand. Liver Cancer, 2019, 8, 524-526.	4.2	0
39	Mediterranean Diet and NAFLD: What We Know and Questions That Still Need to Be Answered. Nutrients, 2019, 11, 2971.	1.7	57
40	Antimicrobial treatment with the fixed-dose antibiotic combination RHB-104 for Mycobacterium avium subspecies paratuberculosis in Crohnâ€™s disease: pharmacological and clinical implications. Expert Opinion on Biological Therapy, 2019, 19, 79-88.	1.4	14
41	Regression of Fibrosis After Direct-acting AntiviralsÂTreatment of Patients withÂHepatitis C Virus Cirrhosis: Transposability to Nondecompensated Patients. Journal of Clinical and Experimental Hepatology, 2019, 9, 546.	0.4	0
42	Improvement in hepatitis C virus patients with advanced, compensated liver disease after sustained virological response to direct acting antivirals. European Journal of Clinical Investigation, 2019, 49, e13056.	1.7	30
43	Harmonising proton pump inhibitors treatment in the specialist setting following the SIGE recommendations. Digestive and Liver Disease, 2019, 51, 173-174.	0.4	2
44	Esophageal baseline impedance levels allow the identification of esophageal involvement in patients with systemic sclerosis. Seminars in Arthritis and Rheumatism, 2018, 47, 569-574.	1.6	5
45	Proton pump inhibitors: use and misuse in the clinical setting. Expert Review of Clinical Pharmacology, 2018, 11, 1123-1134.	1.3	112
46	Bleeding after paracentesis in patients with decompensated cirrhosis and acute kidney injury: The perfect storm. Liver International, 2018, 38, 2101-2101.	1.9	1
47	A safety review of proton pump inhibitors to treat acid-related digestive diseases. Expert Opinion on Drug Safety, 2018, 17, 785-794.	1.0	24
48	NASH-related and cryptogenic cirrhosis similarities extend beyond cirrhosis. Journal of Hepatology, 2018, 69, 972-973.	1.8	4
49	Effects of bariatric surgery on the esophagus. Current Opinion in Gastroenterology, 2018, 34, 243-248.	1.0	12
50	The appropriate use of proton-pump inhibitors. Minerva Medica, 2018, 109, 386-399.	0.3	46
51	Liver Stiffness Improvement Is Associated With Amelioration of Indirect Parameters of Portal Hypertension One Year After Sustained Virological Response to Direct Acting Antivirals in Chronic Hepatitis C Patients. American Journal of Gastroenterology, 2018, 113, S577.	0.2	0
52	Proximal Esophageal Baseline Impedance Levels are Able to Discriminate between Scleroderma Patients with and without Esophageal Involvement. Gastroenterology, 2017, 152, S654.	0.6	0
53	Different Proton Pump Inhibitors are Equally Effective in Inducing Endoscopic and Histologic Remission in Patients with Proton Pump Inhibitor-Response Esophageal Eosinophilia. Gastroenterology, 2017, 152, S860-S861.	0.6	0
54	The Effect of Bile Reflux on Baseline Impedance Value and Chemical Clearance in Patients with NERD. Gastroenterology, 2017, 152, S654.	0.6	1

#	Article	IF	Citations
55	Proton Pump Inhibitor Therapy Improves Esophageal Symptoms by Restoring a Normal Esophageal Peristalsis in Patients with Proton Pump Inhibitor-Response Esophageal Eosinophilia. Gastroenterology, 2017, 152, S860.	0.6	0
56	A review of pharmacotherapy for treating gastroesophageal reflux disease (GERD). Expert Opinion on Pharmacotherapy, 2017, 18, 1333-1343.	0.9	39
57	Vonoprazan fumarate for the management of acid-related diseases. Expert Opinion on Pharmacotherapy, 2017, 18, 1145-1152.	0.9	43
58	Anti-TNF therapy is able to stabilize bowel damage progression in patients with Crohnâ€™s disease. A study performed using the LÃ©mann Index. Digestive and Liver Disease, 2017, 49, 175-180.	0.4	25
59	Drugs for improving esophageal mucosa defense: where are we now and where are we going?. Annals of Gastroenterology, 2017, 30, 585-591.	0.4	26
60	Relevance of Measuring Substances in Bronchoalveolar Lavage Fluid for Detecting Aspiration-associated Extraesophageal Reflux Disease. Journal of Neurogastroenterology and Motility, 2017, 23, 318-319.	0.8	1
61	Epidemiology and natural history of gastroesophageal reflux disease. Minerva Gastroenterology, 2017, 63, 175-183.	0.3	30
62	Complexity and diversity of gastroesophageal reflux disease phenotypes. Minerva Gastroenterology, 2017, 63, 198-204.	0.3	1
63	Pathophysiological Studies Are Mandatory to Understand the Benefit of Proton Pump Inhibitors in Patients with Idiopathic Pulmonary Fibrosis. Journal of Neurogastroenterology and Motility, 2016, 22, 710-711.	0.8	0
64	Mo1173 Association Between Eosinophilic Esophagitis and Helicobacter pylori Infection: Preliminary Results of a Multicenter Study. Gastroenterology, 2016, 150, S657-S658.	0.6	1
65	Reduction of hexavalent chromium by fasted and fed human gastric fluid. I. Chemical reduction and mitigation of mutagenicity. Toxicology and Applied Pharmacology, 2016, 306, 113-119.	1.3	21
66	Functional Heartburn Overlaps With Irritable Bowel Syndrome More Often than GERD. American Journal of Gastroenterology, 2016, 111, 1711-1717.	0.2	55
67	Vonoprazan for treatment of gastroesophageal reflux: pharmacodynamic and pharmacokinetic considerations. Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 1333-1341.	1.5	17
68	The natural history of gastro-esophageal reflux disease: a comprehensive review. Ecological Management and Restoration, 2016, 30, 1-9.	0.2	49
69	Sa1268 Feasibility of High Resolution Impedance Manometry in Assessing Barrett's Esophagus Extension. Gastroenterology, 2016, 150, S263-S264.	0.6	0
70	Esophagogastric junction morphology is associated with a positive impedanceâ€<scp>pH</scp> monitoring in patients with <scp>GERD</scp>. Neurogastroenterology and Motility, 2015, 27, 1175-1182.	1.6	91
71	Esophagogastric junction contractility for clinical assessment in patients with <scp>GERD</scp>: a real added value?. Neurogastroenterology and Motility, 2015, 27, 1423-1431.	1.6	85
72	Impedance-detected Symptom Association and Number of Reflux Episodes as Pre-treatment Parameters That Predict Outcomes of Gastroesophageal Reflux Disease Patients. Journal of Neurogastroenterology and Motility, 2015, 21, 292-293.	0.8	2

#	Article	IF	Citations
73	Optimal management of constipation associated with irritable bowel syndrome. Therapeutics and Clinical Risk Management, 2015, 11, 691.	0.9	11
74	Antiâ€“Tumor Necrosis Factor Antibodies for Prevention of Crohnâ€™s Disease Recurrence After Surgery: More Than a Hope. Clinical Gastroenterology and Hepatology, 2015, 13, 1856.	2.4	1
75	Measurement of oro-caecal transit time by magnetic resonance imaging. European Radiology, 2015, 25, 1579-1587.	2.3	13
76	Mo1128 Are Baseline Impedance Levels Assessed During Esophageal Impedance Manometry Helpful in Discriminating Patients With Gastroesophageal Reflux Disease From Those Without? A Pilot Study. Gastroenterology, 2015, 148, S-614-S-615.	0.6	0
77	Not All Patients With Non-erosive Reflux Disease Share Psychological Distress as Main Mechanism of Disease. Journal of Neurogastroenterology and Motility, 2014, 20, 129-130.	0.8	2
78	Esophageal motility abnormalities in gastroesophageal reflux disease. World Journal of Gastrointestinal Pharmacology and Therapeutics, 2014, 5, 86.	0.6	68
79	Comment on â€œImpairment of chemical clearance is relevant to the pathogenesis of refractory reflux oesophagitisâ€•by Marzio Frazzoni et al. [Digestive and Liver Disease 2014;46:596â€“602]. Digestive and Liver Disease, 2014, 46, 1052.	0.4	0
80	Microscopic esophagitis distinguishes patients with non-erosive reflux disease from those with functional heartburn. Journal of Gastroenterology, 2013, 48, 473-482.	2.3	157
81	Tu1805 Different Accuracy of Various Impedance-pH Normal Values in Diagnosing GERD in Patients With Proven Reflux Disease. Gastroenterology, 2013, 144, S-850-S-851.	0.6	0
82	Tu1771 Impedance-pH Explores With More Accuracy Than pH-Metry Alone the Relationship Between Aspiration of Gastric Contents and Gastroesophageal Reflux in Patients With Idiopathic Pulmonary Fibrosis. Gastroenterology, 2013, 144, S-840-S-841.	0.6	0
83	Adalimumab Is More Effective Than Azathioprine and Mesalamine at Preventing Postoperative Recurrence of Crohn's Disease: A Randomized Controlled Trial. American Journal of Gastroenterology, 2013, 108, 1731-1742.	0.2	187
84	Gastro-oesophageal reflux and gastric aspiration in idiopathic pulmonary fibrosis patients. European Respiratory Journal, 2013, 42, 1322-1331.	3.1	194
85	Gastroesophageal Reflux is More Relevant Than Motor Dysfunction in Provoking Non-Cardiac Chest Pain. Gastroenterology, 2011, 140, S-251-S-252.	0.6	0
86	OC.03.6: PREVALENCE OF ESOPHAGEAL MOTILITY ABNORMALITIES IN PATIENTS WITH â€œTRUEâ€•NON-EROSIVE REFLUX DISEASE, EROSIVE ESOPHAGITIS, BARRETT ESOPHAGUS AND FUNCTIONAL HEARTBURN. Digestive and Liver Disease, 2011, 43, S125.	0.4	0
87	The added value of impedance-pH monitoring to Rome III criteria in distinguishing functional heartburn from non-erosive reflux disease. Digestive and Liver Disease, 2011, 43, 542-547.	0.4	140
88	Overweight is a risk factor for both erosive and non-erosive reflux disease. Digestive and Liver Disease, 2011, 43, 940-945.	0.4	52
89	Impedance-pH Monitoring Increases the Diagnostic Yield in Endoscopic Negative Patients With Non-Cardiac Chest Pain. Gastroenterology, 2011, 140, S-247-S-248.	0.6	0
90	The Differing Role of Overweight Among the Various Subgroups of Non-Erosive Reflux Disease. Gastroenterology, 2011, 140, S-627.	0.6	0

#	Article	IF	Citations
91	Can We Estimate Oro-Cecal Transit Time Using Magnetic Resonance Imaging (MRI)? A Comparison With Hydrogen Breath Test (H2-BT) in Healthy Volunteers. Gastroenterology, 2011, 140, S-446.	0.6	0
92	Oesophageal motility and bolus transit abnormalities increase in parallel with the severity of gastro-oesophageal reflux disease. Alimentary Pharmacology and Therapeutics, 2011, 34, 476-486.	1.9	172
93	Characteristics of gastro-esophageal reflux episodes in Barrettâ€™s esophagus, erosive esophagitis and healthy volunteers. Neurogastroenterology and Motility, 2010, 22, 1061-e280.	1.6	72
94	Characteristics of Reflux Episodes and Symptom Association in Patients With Erosive Esophagitis and Nonerosive Reflux Disease: Study Using Combined Impedanceâ€“pH Off Therapy. American Journal of Gastroenterology, 2010, 105, 1053-1061.	0.2	190
95	Hepatocellular Carcinoma in Patients With Cryptogenic Cirrhosis. Clinical Gastroenterology and Hepatology, 2009, 7, 580-585.	2.4	48
96	Positive Glucose Breath Testing is More Prevalent in Patients With IBS-like Symptoms Compared With Controls of Similar Age and Gender Distribution. Journal of Clinical Gastroenterology, 2009, 43, 962-966.	1.1	59
97	Hyaluronic acid and aspartate aminotransferase levels normalized by liver function can reflect sinusoidal impairment in chronic liver disease. Liver International, 2006, 26, 439-444.	1.9	2